Substituted pyrrolotriazines as protein kinase inhibitors

US8791257B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jay A. Markwalder · New London, US
• Brian E. Fink · Yardley, US
• Ashvinikumar V. Gavai · Princeton Junction, US
• Liqi He · West Chester, US
• Soong-Hoon Kim · Titusville, US
• Steven P. Seitz · Swarthmore, US

Key dates

• Filing date: Mar 30, 2011
• Grant date: Jul 29, 2014
• Expiry date: Mar 30, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.